Tag: Almirall

SilicoDerm: new modeling techniques for dermatological research

almirallshare- open innovation

SilicoDerm is a research project aimed to develop novel computational drug design methodologies applied to dermatological targets

The application of SilicoDerm computational methodologies will facilitate the identification of active compounds for the treatment of inflammatory skin diseases, specifically atopic dermatitis and psoriasis


Almirall, S.A. and the Electronic and Atomic Protein Modeling Group (EAPM) from the Life Sciences Department of the Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS) have entered into a research collaboration, SilicoDerm, a project focused on computational drug design applied to dermatological therapeutic targets.

SilicoDerm aims to develop novel high-performance computational methodologies that facilitate the identification of active compounds for the treatment of inflammatory skin diseases of Almirall’s interest, such as psoriasis and atopic dermatitis. The project scope encompasses from the development of the computational methodologies for two novel therapeutics targets, to the synthesis and evaluation of the compounds identified in-silico. The new protein-based 3D virtual screening methodologies of SilicoDerm will allow to study thousands of compounds in a faster and a more reliable way than current computational methodologies.

Dr. Jordi Gràcia, Head of Drug Discovery, Almirall, commented: “Our collaboration with BSC is an outstanding opportunity for Almirall R&D. The application of these novel computational methodologies for drug design will facilitate the identification of new compounds, and therefore, reduce the time of development of new drugs that will broaden our spectrum of potential treatments for unmet medical needs in patients with skin diseases.”

At the same time, Dr. Víctor Guallar, leader of the Electronic and Atomic Protein Modelling Group from the Barcelona Supercomputing Center-Centro Nacional de Supercomputación  (BSC-CNS), stated: “This project shows the maturity of the modeling techniques developed at BSC to address real life drug design projects. We invested many years of research to get here.”

This project is being financed by the Ministry of Science, Innovation and Universities (MICINN) through the grants Reto de Colaboración 2017 and co-financed by FEDER funds from the European Commission.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenue in 2017 was 755.8 million euros and more than 1,830 employees are devoted to Science.

For more information, please visit almirall.com linkedin.com/company/almirall

About Barcelona Supercomputing Center

BSC is the leading supercomputing center in Spain. It specializes in high-performance computing. It has a dual role: providing infrastructure and a supercomputing service for Spanish and European scientists, and generating knowledge and technology to be transferred to society. It is a Severo Ochoa Center of Excellence, a member of the top-level European research infrastructure PRACE (Partnership for Advanced Computing in Europe) and manages the Spanish Supercomputing Network (RES). BSC is a public consortium owned by the Spanish Government Ministry of Science, Innovation and Universities (60%), the Catalan Government Department of Business and Knowledge (30%) and the Polytechnic University of Catalonia (10%).

Almirall + Evotec = first-in-class dermatological therapies

AlmirallShare

Almirall and Evotec enter into research collaboration in the field of dermatological diseases

Collaboration leverages a novel approach to disrupt cell signaling, validated by Evt Innovate


Barcelona, 03th October 2018 – Almirall, S.A. (Spanish Stock Exchange. ticker: ALM) and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) recently announced that they have entered into a research collaboration with the aim to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. The collaboration combines Evotec’s cutting-edge drug discovery and pre-clinical development platforms with Almirall’s leading expertise in dermatology diseases.

Under the terms of the agreement, Evotec will receive research funding and may be eligible to receive discovery, pre-clinical, clinical and sales milestone payments as well as tiered royalties.

Dr. Bhushan Hardas, Executive Vice President R&D, Chief Scientific Officer of Almirall, said: “Our R&D strategy focuses towards achieving innovative and breakthrough products to cover patients’ unmet needs. This partnership with Evotec, an expert in delivering fast growing and profitable drug discovery and development business, represents a step forward in offering outstanding solutions for the treatment of dermatology diseases with the best technology available and with substantial benefit to patients suffering from dermatological disorders.”

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said: “Evotec is pleased to partner with Almirall in the field of dermatology, who is a globally recognised leader in the field. The goal is to jointly address highly validated targets via a new approach that has the potential to deliver superior first-in-class drug products. This platform enables disruption of cell signaling via a new approach that has been identified and developed by Evotec scientists in Toulouse and is expected to deliver many more drug discovery opportunities.”

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenue in 2017 was 755.8 million euros and more than 1,830 employees are devoted to Science.

For more information, please visit almirall.com    linkedin.com/company/almirall

About Evotec AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.